Recent VIRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 10:10:04 PM
- Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 11:15:25 AM
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 11:05:00 AM
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan • GlobeNewswire Inc. • 08/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:46:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2024 11:12:33 PM
- Viracta Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 05/17/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:26:48 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 08:23:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:34:41 PM
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 09:04:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:34:03 PM
- Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan • GlobeNewswire Inc. • 04/01/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 10:04:14 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:19:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:12:12 PM
- Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/07/2024 09:05:00 PM
- Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 01:40:23 AM
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM